| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Ionetix | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $98.68M | Series F | 8/7/2024 | $62.72M | $266.93M | $1.40 | Eli Lilly, POINT Biopharma Global | ||||
 | LightForce | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $150.18M | Series D | 8/2/2023 | $80M | $403.11M | $18.01 | Ally Bridge Group, Transformation Capital, CareCapital, Omega Venture Partners, Matter Venture Partners, American Association of Orthodontics, Kleinger Perkins, Tyche Partners, Matrix Partners | ||||
 | Lumicell | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $119.14M | Series BB | 5/6/2025 | $38.98M | $147.81M | $1.16 | Undisclosed Investors | ||||
 | Medely | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $134.93M | Series C | 3/15/2022 | $90M | $735.36M | $32.61 | General Catalyst, Mayhaw Capital | ||||
 | Pendulum Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $121.76M | Series C | 6/30/2023 | $64M | $308.05M | $3.24 | Meritech Capital, Sequoia Capital, True Ventures, Khosla Ventures, Fonterra | ||||
 | Qventus | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $155.63M | Series D-1 | 1/13/2025 | $35.81M | $400.12M | $7.95 | KKR, Bessemer Venture Partners, Northwestern Medicine, HonorHealth, Allina Health | ||||
 | SPR Therapeutics | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $104.49M | Series D-1 | 2/1/2024 | $25.64M | $263.67M | $27.44 | Revelation Partners, RC Capital, Mutual Capital Partners | ||||
 | Third Arc Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $197.75M | Series A | 7/16/2024 | $165M | $305.43M | $2.10 | Vida Ventures, Cormorant Asset Management, Hillhouse Investment, Omega Funds, Goldman Sachs, BVF Partners, T. Rowe Price Associates, Janus Henderson Investors, abrdn, Marshall Wace, Foresite Capital, Logos Capital, Freepoint Capital Group, AbbVie Ventures | ||||
 | Tia | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $176.48M | Series D-1 | 9/30/2025 | $20M | $87.68M | $0.24 | Undisclosed Investors | ||||
 | Vilya | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Alto Neuroscience | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $253.17M | Series C | 11/21/2023 | $50.31M | $235.65M | $4.71 | InVivium Capital, Franklin Templeton, Point72, Eli Lilly and Company, Alexandria Venture Investments, Alpha Wave Ventures, Lightswitch Capital, Alkeon Capital, WhatIf Ventures, Windham Venture Partners | ||||
 | Alto Pharmacy | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $670.55M | Series FF | 9/25/2023 | $101.74M | $799.9M | $6.14 | What If Ventures | ||||
 | Aspen Neuroscience | Healthcare Biotech & Pharma | Low | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $339.74M | Series C | 11/20/2025 | $115.62M | $339.66M | $1.52 | OrbiMed, ARCH Venture Partners, Frazier Healthcare Partners, Revelation Partners, Medical Excellence Capital, S32, Axon Ventures, LYFE Capital, LifeForce Capital, Kite, Balyasny Asset Management, Cormorant Asset Management, Prebys Ventures | ||||
 | Carbon Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $688.42M | Super Series Senior-2 | 6/4/2025 | $20.2M | $485.04M | $1.71 | Undisclosed Investors | ||||
 | Crystalys Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $102.40K | -- | 1 | -- | Not available | -- | -- | $335M | Series B | 7/22/2026 | $130M | $568.22M | $1.23 | Frazier Life Sciences, Wellington Management, HBM Healthcare Investments, Soleus Capital, Cormorant Asset Management, Trails Edge Capital Partners, Pivotal bioVenture Partners, KCap Biotechnology, Novo Holdings, SR One, Catalys Pacific, Perceptive Advisors, Lightstone Ventures, AN Venture Partners, Abrdn, KB Investments, Pontifax, Longwood Fund, Alexandria Venture Investments, Wedbush Healthcare Partners, Prebys Ventures | ||||
 | Ensoma | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $250.75M | Series B-1 | 7/2/2025 | $45.2M | $281.79M | $1.09 | Undisclosed Investors | ||||
 | Forward | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.94B | Series E-2 | 8/5/2024 | $146.32M | $928.18M | $5.85 | Undisclosed Investors | ||||
 | Harbor Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $384.26M | Series A-4-4 | 2/20/2026 | $45M | $436.68M | $0.71 | Undisclosed Investors | ||||
 | Hazel Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $364.29M | Series E | 6/9/2026 | $99.03M | $396.96M | $2.40 | Undisclosed Investors | ||||
 | Healthie | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $39.78M | Series B | 10/15/2024 | $23M | $273.02M | $11.77 | TCV, Birchmere Ventures, Velvet Sea Ventures, Greymatter, Watershed | ||||
 | Inquis Medical | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $141.46M | Series C | 1/12/2026 | $75M | $370.67M | $0.86 | Undisclosed Investor | ||||
 | IntelyCare | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $232.77M | Series CR-B | 12/23/2025 | $25.64M | $3.21B | $41.67 | Undisclosed Investors | ||||
 | Levels | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $365.48M | Series A-1 | 4/20/2022 | $46.01M | $311.7M | $10.44 | Andrea Funsten, Ben Gilbert, David Rosenthal, Lenny Rachitsky, Mario Gabriele, Mat Fraser, Moshe Lifschitz, Niv Dror, Andreessen Horowitz, Trust Ventures, Shrug Capital, TriplePoint Capital, Long Journey Ventures | ||||
 | Nomi Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $109.03K | -- | 1 | Not available | -- | -- | $192.04M | Series B | 6/29/2023 | $118.25M | $1.71B | $68.85 | Undisclosed Investors | ||||